A study shows that L. johnsonii modulates macrophages to reduce intestinal inflammation in mice, suggesting potential therapeutic effects against ETEC-induced injuries.
Enterotoxigenic Escherichia coli (ETEC) is a major diarrheal pathogen in humans and animals, causing intestinal barrier dysfunction and inflammatory bowel diseases.Limosilactobacillus johnsonii (L.johnsonii), a well-characterized probiotic, has been shown to alleviate diarrheal diseases by modulating macrophage function.This study aimed to elucidate the molecular mechanisms by which L. johnsonii confers protection against ETEC-induced intestinal injury.Eighteen 4-week-old male C57BL/6 mice
No takes yet. Share an insight, caveat, or question.
Ge et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: